NCI awarded a 5-year, $11 million grant to NYU Langone Health’s Ronald O. Perelman department of dermatology to develop biomarkers that can predict whether immunotherapy will be effective for specific patients.
Archive | Health Professionals
NCI awards $11 million grant to NYU Langone to develop immunotherapy biomarkers
Posted in Melanoma News, Health Professionals, Of Interest
Targeted Drug Combination Can Have Long-Lasting Results for Some With BRAF-Mutated Melanoma
For about half of patients with advanced melanoma, there is only one treatment choice: immunotherapy. But for those whose late-stage melanoma expresses a BRAF gene mutation, there’s another option – combinations of targeted drugs.
Posted in Melanoma News, Health Professionals, Of Interest
A prospective trial of adjuvant therapy for high-risk uveal melanoma: Assessing 5-year survival outcomes
Because survival after diagnosis of uveal melanoma metastasis is poor, researchers conducted an adjuvant trial of sequential, low-dose dacarbazine (DTIC) and interferon-alpha-2b (IFN-??2b) in patients with cytogenetic high-risk uveal melanoma.
Posted in Melanoma News, Health Professionals, Clinical Trials
Future of Treating Melanoma
Jeffrey S. Weber, MD, PhD: This has been extremely informative. But before we end this discussion, I’d like to get some final thoughts from each of the panelists. Dr Jason Luke?
Posted in Melanoma News, Health Professionals, Video Reports
